Express News | Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Es-Sclc by Nmpa
Junshi Biosciences (688180.SH): There are currently no COVID-19 vaccine products in the development pipeline.
Junshi Bio (688180.SH) stated on the investor interaction platform on June 12 that there is currently no vaccine product against COVID-19 in the company's research and development pipeline.
Junshi Bio (688180.SH): The new indication for the use of Toripalimab monotherapy in first-line treatment for extensive-stage small cell lung cancer has been approved for market application.
On June 12th, Gelunhui reported that Junshi Bio (688180.SH) has received a 'Pharmaceutical Registration Certificate' approved and issued by the National Medical Products Administration for Toripalimab (Commodity Name: Tuoyi, Product Code: JS001), which is used in combination with Icotinib and Platinum-based drugs for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) as a new indication. Due to the commercialization of medicine that can be affected by certain uncertainties after obtaining market approval.
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment
Shanghai Junshi Biosciences (SHA:688180, HKG:1877) achieved the primary endpoints of a phase 3 trial for its toripalimab advanced liver cancer treatment, according to a Wednesday filing with the Shang
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results
Shanghai Junshi Biosciences (HKG:1877) announced positive results from a Phase III clinical trial testing its drug toripalimab in combination with bevacizumab for advanced hepatocellular carcinoma (HC
Express News | Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined With Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
Hong Kong stocks fluctuate | Junshi Bio (01877) opens nearly 6% higher. The phase III clinical study of Toripalimab combined with Bevacizumab has achieved the main research endpoint.
Junshi Bio (01877) opened nearly 6% higher and, as of press time, rose 5.75%, to HKD 12.88, with a turnover of HKD 723,900.
Express News | Shanghai Junshi Biosciences - Phase III Clinical Study of Toripalimab in Combination With Bevacizumab Met Primary Endpoint
Hong Kong Stock News | Junshi Bio (01877) rose nearly 5%. 1.7115 million restricted shares will be listed and circulated on June 17th.
Junshi Bio (01877) rose nearly 5%, as of press time, up 4.94% at HKD 12.320, with a turnover of HKD 8.9011 million.
Junshi Bio (01877): 1.7115 million restricted shares will be listed for circulation on June 17th.
Junshi Bio (01877) announced that this listing of restricted stocks is from the second exercise period of the company's 2018 stock-based incentive plan. The quantity of restricted stocks in this listing is 1.7115 million shares, accounting for 0.17% of the company's total share capital as of the date of this announcement. The restricted period is three years from the day of exercise, involving 205 shareholders. This portion of the restricted shares will be listed on the market from June 17, 2024.
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Junshi Biotech (688180.SH): spent a total of 29.88 million yuan to buy back 780,000 shares
Gelonghui, May 31 | Junshi Biotech (688180.SH) announced that as of May 31, 2024, the company had repurchased 781,486 shares through centralized bidding transactions, accounting for 0.0793% of the company's total share capital. The highest repurchase transaction price was RMB 41.69 per share, the lowest price was RMB 29.21 yuan/share, and the total amount of capital paid was RMB 29,883,225.58 (excluding transaction fees such as stamp duty and transaction fees).
Changes in Hong Kong stocks | Junshi Biotech (01877) rose more than 5% at the end of the session, treprilizumab ushered in accelerated volume and the company's revenue increased by more than 49% in the first quarter
The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 5% at the end of the session. As of press release, it had risen 4.53% to HK$12, with a turnover of HK$15.8876 million. According to the news, Junshi Biotech previously announced first-quarter results, with revenue of about 381 million yuan, an increase of 49.24% year on year; net loss attributable to shareholders of listed companies was about 283 million yuan, a year-on-year decrease of 47.92%. The increase in the company's revenue is mainly due to the increase in sales revenue of commercial drugs. Among them, the core product treprilizumab injection achieved sales revenue of about 307 million yuan in the domestic market, an increase of about 300 million yuan over the previous year
Junshi Biotech (01877): Tang Yi nominated as non-executive director candidate
Junshi Biotech (01877) issued an announcement. The company held the 32nd session of the 3rd board of directors on May 30, 2024...
Institutions Profited After Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Market Cap Rose HK$1.6b Last Week but Individual Investors Profited the Most
Key Insights Significant control over Shanghai Junshi Biosciences by individual investors implies that the general public has more power to influence management and governance-related decisions The
Junshi Biotech (688180.SH): A total of 781,500 shares have been repurchased
Gelonghui, April 30, 丨 Junshi Biotech (688180.SH) announced that as of April 30, 2024, the company had repurchased 781,486 shares through centralized bidding transactions, accounting for 0.0793% of the company's total share capital. The highest repurchase transaction price was RMB 41.69 per share, the lowest price was RMB 29.21 yuan/share, and the total amount of capital paid was RMB 29,883,225.58 (excluding transaction fees such as stamp duty and transaction fees).
Changes in Hong Kong stocks | Junshi Biotech (01877) rose more than 6% in the afternoon, Q1 revenue increased 49.24% year-on-year, and losses narrowed by 47.92%
The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 6% in the afternoon. As of press release, it had risen 4.24% to HK$11.3, with a turnover of HK$14.146,600. According to the news, Junshi Biotech announced its results for the first quarter of 2024, with operating income of about 381 million yuan, an increase of 49.24%; net loss attributable to shareholders of listed companies was about 283 million yuan, a year-on-year narrowing of 47.92%; and a basic loss of 0.29 yuan per share. During the reporting period, the increase in the company's revenue was mainly due to the increase in sales revenue of commercial drugs. Among them, the core product, treprilizumab injection (
君實生物:海外監管公告 - 上海君實生物醫藥科技股份有限公司2024年第一季度報告
Junshi Biotech (688180.SH): Net loss of 283 million yuan in the first quarter
Gelonghui, April 29丨Junshi Biotech (688180.SH) released its first quarter report. Operating revenue was 380 million yuan, up 49.24% year on year, net loss of 283 million yuan, net loss of 307 million yuan after deducting non-net loss of 307 million yuan, and basic earnings per share.
君實生物:2023年度報告
No Data